Mandate

Vinge advises Bonnier in connection with the acquisition of one of Finland’s leading publishers

May 02, 2011

On Friday, 29 April 2011, Bonnier announced that it had acquired WSOY, Finland’s leading publisher within general literature, from Sanoma. Together with the existing stake in Tammi, the acquisition will strengthen Bonnier’s position as a general literature publisher in Finland. At the same time, Sanoma acquired Bonnier Education and Tammi Learning from Bonnier. The transactions strengthen both Bonnier and Sanoma’s focus on their respective core operational areas. The acquisition of WSOY is subject to approval by the competent competition authority.

Vinge advised Bonnier in respect of all three acquisitions. Vinge’s team consisted of, among others, responsible partner Malin Leffler and associates Jonas Johansson and Nicolina Kindblom as well as paralegal Ida Norlin.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024